U.S. Claims Data Show That Biogen Idec's Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients

BURLINGTON, Mass., Nov. 24, 2014/ PRNewswire/-- Decision Resources Group finds that, according to U.S. patient-level claims data, Biogen Idec's Tecfidera, the third-to-market oral disease modifying therapy for multiple sclerosis, captured nearly half of second-line share and 7 percent of first-line share among newly diagnosed MS patients whose prescription...